UBS lowered the firm’s price target on Veeva (VEEV) to $200 from $280 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva price target lowered to $296 from $330 at JPMorgan
- Veeva upgraded to Equal Weight from Underweight at Morgan Stanley
- Veeva price target lowered to $295 from $325 at Mizuho
- YCANTH Phase 3 Wart Study Puts Verrica in Focus While Veeva Extends Its Clinical Footprint
- Veeva assumed with a Sell at Goldman Sachs